Lv3
376 积分 2023-09-06 加入
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
27天前
已完结
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
27天前
已完结
LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
1个月前
已完结
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study
1个月前
已完结
P1.09-25 The Use of In-Situ RNA Analysis in the Detection of Metastatic HPV Mediated Squamous Cell Carcinoma to the Lung with p16 Correlation
1个月前
已完结
Understanding the tumor immune microenvironment (TIME) for effective therapy
2个月前
已完结
Innovative immunotherapy approaches: harnessing synergy of dual checkpoint blockade in oncology
2个月前
已完结
Discovery of Environment-Sensitive Near Infrared SHP2-Targeting Fluorescent Ligands for Living Cells and Tissue Section Imaging
2个月前
已完结
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2个月前
已完结
Combination Approaches to Target PD-1 Signaling in Cancer
2个月前
已完结
皖公网安备34019202002308
